| Drug Name |
Daratumumab |
| Drug ID |
BADD_D00582 |
| Description |
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab.[A7935] It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.[A199002]
Daratumumab was granted FDA approval on 16 November 2015.[L13290] It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.[L13290,L13296] |
| Indications and Usage |
For the treatment of patients with multiple myeloma who have received at least three prior lines of therapy (a proteasome inhibitor (PI) and an immunomodulatory agent) or who are double-refractory to a PI and an immunomodulatory agent. This indication was approved by accelerated approval based on response rate. |
| Marketing Status |
Prescription |
| ATC Code |
L01FC01 |
| DrugBank ID |
DB09331
|
| KEGG ID |
D10777
|
| MeSH ID |
C556306
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
71124-0007; 57894-505; 57894-502 |
| Synonyms |
daratumumab | humax-CD38 | humax-CD 38 | Darzalex |
